Table 1.
Patient characteristics
| Disease type | Disease status | Stage | IPI | Prior lines of therapy | Double/triple hit by FISH | Target | Max diameter (cm) | Ortho gonal diameter (cm) | Cross product (cm2) | Total dose (Gy) | Fra ctions | Concurrent systemic bridging therapy | Radiation completed days before CAR-T | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | DLBCL | Primary re fractory | III/IV | 5 | 2 | No | Abdomen | 26.2 | 16.4 | 429.68 | 12 | 4 | Oral cyclo-phosphamide, dexamethasone | −27 |
| Patient 2 | DLBCL | Relapsed re fractory | I/II | 3 | 5 | Yes | LLE/groin | 18.1 | 14.0 | 253.4 | 20 | 5 | Oral cyclo-phosphamide, dexamethasone | −7 |
| Patient 3 | TFL | Primary re fractory | III/IV | 4 | 5 | No | Right neck | 3.7 | 23 | 8.51 | 30 | 10 | rituximab, dexamethasone | −15 |
| Patient 4 | TFL | Relapsed re fractory | I/II | 2 | 3 | Yes | Abdomen | 17.7 | 16.5 | 292.05 | 30 | 10 | Dexamethasone | −8 |
| Patient 5 | DLBCL | Primary re fractory | I/II | 2 | 2 | Yes | Abdomen | 5.9 | 3.1 | 18.29 | 9 | 3 | Rituximab, gemcitabine, oxaliplatin | −13 |
| Patient 6 | TFL | Primary re fractory | III/IV | 3 | 3 | Yes | Left hip | 4.3 | 2.1 | 9.03 | 30 | 10 | None | −15 |
| Patient 7 | DLBCL | Primary re fractory | I/II | 1 | 2 | Yes | Abdomen | 12.4 | 9.3 | 115.32 | 13 | 6 | None | −13 |
| Patient 8 | DLBCL | Relapsed re fractory | III/IV | 4 | 2 | Yes | Left hip | 29.4 | 10.8 | 317.52 | 36.5 | 14 | Rituximab, gemcitabine, oxaliplatin | N/A |
| Patient 9 | DLBCL | Relapsed re fractory | III | 2 | 2 | No | Abdomen | 10.0 | 9.0 | 90 | 6 | 3 | None | −24 |
| Patient 10 | DLBCL | Primary re fractory | III/IV | 2 | 3 | No | LLE/groin | 5.5 | 2.5 | 13.75 | 30 | 10 | Oral cyclo phosphamide, dexamethasone | −12 |
| Patient 11 | DLBCL | Primary re fractory | III/IV | 3 | 2 | Unknown | Abdomen | 7.0 | 5.1 | 35.7 | 20 | 5 | None | −8 |
| Patient 12 | DLBCL | Primary re fractory | III | 3 | 3 | No | Left chest wall | 13.5 | 10.0 | 135 | 6 | 3 | Obinutuzumab | −6 |
| Median | 3 | 2 | 102.7 | 20 | −13 |
Abbreviations: DLBCL = diffuse large B-cell lymphoma; IPI = international prognostic index for lymphoma; LLE = left lower extremity; N/A = not applicable; TFL = transformed follicular lymphoma.
All patients were refractory to their most recently received line of chemotherapy. Primary refractory indicates disease that did not respond to any prior chemotherapy. Relapsed refractory indicates disease that responded to prior therapy but was refractory to the most recent line of therapy.